Provided herein are RET kinase inhibitors according to the formula:
pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R
1
, n, X
1
, X
2
, X
3
, X
4
, and R
2
have the meanings given in the specification.
[EN] COMPOUNDS USEFUL FOR INHIBITING RET KINASE<br/>[FR] COMPOSÉS UTILES POUR INHIBER LA KINASE RET
申请人:LILLY CO ELI
公开号:WO2021222017A1
公开(公告)日:2021-11-04
Provided herein are RET kinase inhibitors according to the formula (I): pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.